The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis.
 
Andrea Necchi
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Pierre Fabre; Seagen
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Celgene; Merck Sharp & Dohme; Roche
 
Gregory Russell Pond
No Relationships to Disclose
 
Nicola Nicolai
No Relationships to Disclose
 
Nabil Adra
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Nasser H. Hanna
No Relationships to Disclose
 
Roberto Salvioni
No Relationships to Disclose
 
Lawrence H. Einhorn
Stock and Other Ownership Interests - Amgen; Biogen
Consulting or Advisory Role - Celgene; ZIOPHARM Oncology
 
Costantine Albany
Consulting or Advisory Role - Seagen
Speakers' Bureau - Bayer